Navigation Links
Models developed from the PLCO may help identify at-risk patients for adverse smoking outcomes
Date:10/26/2012

Risk prediction models developed from an ancillary study of the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) may be useful in the public health sector for identifying individuals who are at risk for adverse smoking outcomes, such as relapse among former smokers and continued smoking among current smokers, and those who may benefit from relapse prevention and smoking cessation interventions according to a study published October 26 in the Journal of the National Cancer Institute.

With a projected 226,160 new cases of lung cancer and 160,340 lung cancer deaths expected in the U.S. in 2012, researchers are looking at lung cancer screenings as a way to alter peoples' smoking behaviors. Although smoking abstinence is the most effective way to lower lung cancer mortality, both early detection and treatment of the disease may also lower mortality. Both the PLCO and the National Lung Screening Trial (NLST) have gathered data to determine whether screening can lower lung cancer mortality; however, the effects that screening has on smoking behavior is unknown.

To determine the effects of cancer screening on smoking behavior, Kathryn L. Taylor, Ph.D., of the Lombardi Comprehensive Cancer Center at Georgetown University, and colleagues, gathered data from participants who had completed a baseline questionnaire at PLCO trial enrollment and a supplemental questionnaire 4 years after enrollment, which assessed variables such as family history of cancer, comorbidity, and tobacco use. Multivariable logistic regression models were used to predict smoking status once the supplemental questionnaire was completed.

The researchers found that of the 31,694 former smokers on the baseline questionnaire, 1,042 had relapsed, and of the 6,807 current smokers, 4,439 had continued smoking on the supplemental questionnaire. Both relapse and continued smoking were statistically significantly linked with demographic, medical, and tobacco-related characteristics. "The relapse prediction model had excellent discrimination and calibration and suggested that relapse was more likely among longer-term smokers, recent quitters, smokers of light or ultra-light cigarettes, and pipe or cigar smokers," the researchers write, adding that the success of these models, "suggest important variables that should be considered in the development of effective intervention methods for long-term, heavily dependent smokers who are likely to be well represented in lung cancer-screening programs."


'/>"/>
Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Genetically-engineered preclinical models predict pharmacodynamic response
2. TRPM7 protein key to breast cancer metastasis in animal models
3. Heterogeneous ER+ breast cancer models allow more accurate drug testing
4. Internists express support for new payment and delivery models as basis for replacing SGR
5. Super Models Line Up to Walk The Catwalk and Celebrate Vogue's Fashion Night Out in LA
6. Strategy developed to improve delivery of medicines to the brain
7. Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
8. Heroes of Chemistry: Developed new drugs and technology to cut heating and cooling bills
9. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
10. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
11. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/26/2017)... ... 2017 , ... Functional imaging data supports improved cognition in ... today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , It ... improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et al., ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... TaskMate Go. Core benefits and advantages built into the home office sit stand ... look and feel. Ability to gain the benefits embedded in the TaskMate Go ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... development, education, networking and recognition opportunities as well as advocacy for the state ... Holmdel, NJ on February 23. The Council's Innovation Forecast event highlights innovation ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age ... Oxford University predict that 47 percent of all jobs in the United States may ... and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... NEW YORK , February 27, 2017 ... (PII) celebrates the pharmaceutical companies that are most successful at ... ... question: if you gave the same molecule to two different ... it? Based on systematic, objective analysis of each ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The ... a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from ... 9.1% from 2016 to 2027. The market is estimated at $816m ... ... on to discover how you can exploit the future business opportunities ...
(Date:2/27/2017)... and PETACH TIKVAH, Israel , ... (NASDAQ: BCLI), a leading developer of adult stem cell ... June S. Almenoff , M.D., Ph.D., FACP, and ... Board of Directors.  "Dr. Almenoff and ... appointments come at an exciting time for our company," ...
Breaking Medicine Technology: